Cargando…

(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study

OBJECTIVE: To compare (68)Ga-DOTA-DPhe1,Tyr3-octreotate ((68)Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional (111)In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). MATERIALS AND METHODS: This was a single-center prosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavicchioli, Marcelo, Bitencourt, Almir Galvão Vieira, Lima, Eduardo Nóbrega Pereira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864693/ https://www.ncbi.nlm.nih.gov/pubmed/35210659 http://dx.doi.org/10.1590/0100-3984.2021.0038

Ejemplares similares

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET/CT
por: Hou, Jiale, et al.
Publicado: (2021)

Testicular Metastasis of Jejunal Neuroendocrine Tumor on (68)Ga-DOTATATE PET/CT
por: Şahin, Ömer Faruk, et al.
Publicado: (2023)

Diagnostic Efficiency of (68)Ga-DOTATATE PET/CT as Compared to (99m)Tc-Octreotide SPECT/CT and Conventional Morphologic Modalities in Neuroendocrine Tumors
por: Fallahi, Babak, et al.
Publicado: (2019)

The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in Localizing Ectopic ACTH Producing Tumors
por: Gözde Özkan, Zeynep, et al.
Publicado: (2013)

Ileal Neuroendocrin Tumor Metastasis to Breast Diagnosed with Ga-68 DOTATATE PET/CT
por: Sağlampınar Karyağar, Sevda, et al.
Publicado: (2019)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
por: Resch, Katrin, et al.
Publicado: (2022)

Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [(68)Ga]DOTATATE PET/CT
por: D'Souza, Julia C., et al.
Publicado: (2022)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

Diagnosing microscopic pancreatic neuroendocrine tumor using 68-Ga-DOTATATE PET/CT: case series
por: Barrio, Martin, et al.
Publicado: (2018)

Metastatic urinary bladder paraganglioma on Ga-68 DOTATATE PET/CT
por: Ko, Andrew, et al.
Publicado: (2021)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
por: Roden, Anja C., et al.
Publicado: (2022)

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT
por: Schreiter, Nils Friedemann, et al.
Publicado: (2014)

Striking Visualization of Diffuse Congenital Nesidioblastosis on Ga-68 DOTATATE PET/CT
por: Canbaz, Fevziye, et al.
Publicado: (2019)

Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome
por: Jayasekera, Migara, et al.
Publicado: (2023)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

Unusual Increased Blood Pool Activity on (68)Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease
por: Sharma, Akash, et al.
Publicado: (2022)

Comparison of the application of (18)F-FDG and (68)Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study
por: Hu, Xianwen, et al.
Publicado: (2023)

Impact of (68)Ga-DOTATOC PET/CT in comparison to (111)In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report
por: Tolomeo, Anna, et al.
Publicado: (2020)

[68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases
por: Roytman, Michelle, et al.
Publicado: (2021)

(68)Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer
por: Walker, Ronald, et al.
Publicado: (2017)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Incidental primary breast cancer detected on surveillance (68)Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma
por: Ambinder, Emily B., et al.
Publicado: (2020)

(68)Ga DOTATATE Uptake in Hemangioma Simulating Metastasis on PET Imaging: CT helps characterize bone hemangioma that could be wrongly interpreted as skeletal metastases on (68)Ga DOTATATE PET imaging
por: Vertenten, Bart, et al.
Publicado: (2019)

MON-499 Tumor Induced Osteomalacia: (68)Ga-DOTATATE PET/CT Scan For Localization
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2019)

Ga-68 DOTATATE PET/CT in the Evaluation of Paragangliomas and Other Indeterminate Lesions in the Head and Neck
por: Kuker, Russ, et al.
Publicado: (2022)

111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME)
por: Pontico, Mariano, et al.
Publicado: (2020)

The Diagnostic and Grading Accuracy of (68)Ga-DOTATATE and (18)F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms
por: Zhou, Jinxin, et al.
Publicado: (2022)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

The role of [(68) Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST)
por: Aloj, Luigi, et al.
Publicado: (2021)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
por: Chang, Chian A., et al.
Publicado: (2016)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

Comparison of (18)F‐FDG PET/CT and (68)Ga‐DOTATATE PET/CT in the Targeted Imaging of Culprit Tumors Causing Osteomalacia
por: Yu, Hao‐nan, et al.
Publicado: (2021)

(68)Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
por: Boertien, Tessel M., et al.
Publicado: (2020)

A personal acquisition time regimen of (68)Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study
por: Xiao, Jie, et al.
Publicado: (2022)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mof16v7iene181l3o2nad4ior5